| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Smoking Cessation | 38 | 2024 | 541 | 4.450 |
Why?
|
| Mass Screening | 38 | 2023 | 648 | 3.810 |
Why?
|
| Counseling | 28 | 2022 | 350 | 3.760 |
Why?
|
| Pediatric Obesity | 6 | 2024 | 97 | 2.840 |
Why?
|
| Smoking Prevention | 12 | 2020 | 158 | 2.640 |
Why?
|
| Overweight | 11 | 2024 | 238 | 2.560 |
Why?
|
| Primary Health Care | 18 | 2024 | 651 | 2.420 |
Why?
|
| Asthma | 10 | 2024 | 460 | 2.290 |
Why?
|
| Smoking | 20 | 2023 | 826 | 2.190 |
Why?
|
| Health Promotion | 12 | 2022 | 471 | 2.050 |
Why?
|
| School Nursing | 7 | 2022 | 26 | 1.880 |
Why?
|
| School Health Services | 6 | 2024 | 60 | 1.620 |
Why?
|
| Adolescent | 53 | 2024 | 5851 | 1.530 |
Why?
|
| Schools | 8 | 2022 | 150 | 1.490 |
Why?
|
| Behavior Therapy | 8 | 2022 | 161 | 1.440 |
Why?
|
| Pediatrics | 11 | 2024 | 241 | 1.430 |
Why?
|
| Parents | 8 | 2024 | 367 | 1.410 |
Why?
|
| Humans | 151 | 2024 | 59454 | 1.380 |
Why?
|
| Body Mass Index | 10 | 2024 | 831 | 1.350 |
Why?
|
| Advisory Committees | 17 | 2023 | 108 | 1.340 |
Why?
|
| Tobacco Use Disorder | 8 | 2021 | 243 | 1.260 |
Why?
|
| Female | 97 | 2024 | 30766 | 1.260 |
Why?
|
| Male | 77 | 2024 | 27784 | 1.150 |
Why?
|
| Child | 31 | 2024 | 4201 | 1.120 |
Why?
|
| Mindfulness | 2 | 2018 | 66 | 1.000 |
Why?
|
| Professional-Patient Relations | 2 | 2020 | 126 | 0.970 |
Why?
|
| Health Personnel | 5 | 2019 | 342 | 0.960 |
Why?
|
| Health Behavior | 5 | 2022 | 452 | 0.950 |
Why?
|
| Vaping | 3 | 2024 | 44 | 0.940 |
Why?
|
| Adult | 63 | 2024 | 15697 | 0.940 |
Why?
|
| Education, Medical | 4 | 2021 | 178 | 0.850 |
Why?
|
| Preventive Health Services | 12 | 2023 | 72 | 0.840 |
Why?
|
| Hotlines | 2 | 2016 | 21 | 0.840 |
Why?
|
| Weight Loss | 3 | 2014 | 263 | 0.820 |
Why?
|
| Pregnancy Complications | 10 | 2021 | 364 | 0.820 |
Why?
|
| Risk Assessment | 25 | 2023 | 1926 | 0.810 |
Why?
|
| Electronic Nicotine Delivery Systems | 3 | 2024 | 71 | 0.810 |
Why?
|
| Social Support | 5 | 2024 | 355 | 0.800 |
Why?
|
| Qualitative Research | 4 | 2024 | 619 | 0.790 |
Why?
|
| Students, Medical | 3 | 2021 | 247 | 0.790 |
Why?
|
| Patient Navigation | 3 | 2017 | 34 | 0.770 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2024 | 168 | 0.770 |
Why?
|
| Ambulatory Care | 4 | 2015 | 305 | 0.770 |
Why?
|
| Self Efficacy | 3 | 2019 | 194 | 0.760 |
Why?
|
| Body Weight Maintenance | 2 | 2021 | 14 | 0.750 |
Why?
|
| Program Evaluation | 12 | 2019 | 470 | 0.730 |
Why?
|
| Communication | 4 | 2022 | 547 | 0.710 |
Why?
|
| Dental Caries | 4 | 2023 | 25 | 0.700 |
Why?
|
| Massachusetts | 16 | 2024 | 2022 | 0.700 |
Why?
|
| Body Weight | 3 | 2018 | 369 | 0.680 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2023 | 60 | 0.670 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2020 | 64 | 0.670 |
Why?
|
| Motivation | 4 | 2020 | 275 | 0.670 |
Why?
|
| Reward | 2 | 2017 | 83 | 0.670 |
Why?
|
| Interviews as Topic | 7 | 2024 | 484 | 0.670 |
Why?
|
| Obesity | 7 | 2021 | 1166 | 0.660 |
Why?
|
| Capacity Building | 1 | 2019 | 21 | 0.660 |
Why?
|
| Telephone | 3 | 2024 | 115 | 0.650 |
Why?
|
| Cardiovascular Diseases | 7 | 2022 | 789 | 0.630 |
Why?
|
| Directive Counseling | 2 | 2016 | 38 | 0.620 |
Why?
|
| Pain Management | 1 | 2020 | 146 | 0.610 |
Why?
|
| Preceptorship | 1 | 2018 | 41 | 0.610 |
Why?
|
| Chronic Pain | 1 | 2020 | 136 | 0.600 |
Why?
|
| Impulsive Behavior | 1 | 2018 | 28 | 0.590 |
Why?
|
| Feeding Behavior | 3 | 2015 | 254 | 0.580 |
Why?
|
| Depressive Disorder | 3 | 2017 | 279 | 0.570 |
Why?
|
| Surveys and Questionnaires | 12 | 2020 | 2517 | 0.570 |
Why?
|
| Exercise | 4 | 2022 | 883 | 0.550 |
Why?
|
| United States | 28 | 2024 | 7432 | 0.550 |
Why?
|
| Pregnancy | 23 | 2023 | 2215 | 0.540 |
Why?
|
| Attitude to Health | 3 | 2013 | 279 | 0.530 |
Why?
|
| Health Education | 5 | 2020 | 183 | 0.520 |
Why?
|
| Clinical Competence | 5 | 2022 | 683 | 0.520 |
Why?
|
| Primary Prevention | 5 | 2022 | 134 | 0.510 |
Why?
|
| Focus Groups | 4 | 2017 | 288 | 0.510 |
Why?
|
| Medication Adherence | 6 | 2024 | 241 | 0.480 |
Why?
|
| Prediabetic State | 3 | 2022 | 51 | 0.470 |
Why?
|
| Workplace | 2 | 2013 | 169 | 0.470 |
Why?
|
| Life Style | 3 | 2024 | 299 | 0.460 |
Why?
|
| Health Surveys | 3 | 2018 | 299 | 0.460 |
Why?
|
| Middle Aged | 31 | 2024 | 16335 | 0.450 |
Why?
|
| Obstetrics | 3 | 2013 | 80 | 0.440 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2023 | 725 | 0.430 |
Why?
|
| Occupational Health Services | 1 | 2013 | 36 | 0.430 |
Why?
|
| Adolescent Behavior | 7 | 2015 | 186 | 0.430 |
Why?
|
| Attitude of Health Personnel | 4 | 2020 | 552 | 0.430 |
Why?
|
| Early Detection of Cancer | 3 | 2021 | 267 | 0.430 |
Why?
|
| Quality of Life | 7 | 2023 | 1138 | 0.420 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2022 | 635 | 0.410 |
Why?
|
| Cross-Sectional Studies | 8 | 2023 | 2383 | 0.410 |
Why?
|
| Patient Education as Topic | 6 | 2020 | 453 | 0.410 |
Why?
|
| Pilot Projects | 7 | 2022 | 916 | 0.400 |
Why?
|
| Weight Gain | 1 | 2013 | 163 | 0.400 |
Why?
|
| Motor Activity | 1 | 2015 | 333 | 0.390 |
Why?
|
| Text Messaging | 2 | 2024 | 76 | 0.380 |
Why?
|
| Meditation | 1 | 2012 | 54 | 0.380 |
Why?
|
| Papillomavirus Vaccines | 2 | 2023 | 67 | 0.370 |
Why?
|
| Asymptomatic Diseases | 5 | 2023 | 46 | 0.370 |
Why?
|
| Depressive Disorder, Major | 3 | 2023 | 247 | 0.370 |
Why?
|
| Hypertension | 6 | 2022 | 570 | 0.360 |
Why?
|
| Papillomavirus Infections | 2 | 2023 | 120 | 0.360 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2017 | 454 | 0.360 |
Why?
|
| Research Design | 3 | 2021 | 556 | 0.360 |
Why?
|
| Schools, Medical | 3 | 2021 | 142 | 0.350 |
Why?
|
| Aspirin | 2 | 2022 | 167 | 0.350 |
Why?
|
| Interpersonal Relations | 2 | 2013 | 150 | 0.340 |
Why?
|
| Hepatitis B virus | 2 | 2020 | 13 | 0.340 |
Why?
|
| Young Adult | 10 | 2024 | 4274 | 0.340 |
Why?
|
| Risk Factors | 18 | 2022 | 4990 | 0.330 |
Why?
|
| Treatment Outcome | 11 | 2017 | 5287 | 0.330 |
Why?
|
| Community Health Centers | 4 | 2004 | 89 | 0.320 |
Why?
|
| Feasibility Studies | 4 | 2022 | 526 | 0.320 |
Why?
|
| Tobacco Use Cessation | 3 | 2021 | 29 | 0.310 |
Why?
|
| Anti-Retroviral Agents | 2 | 2019 | 73 | 0.310 |
Why?
|
| Nicotine | 4 | 2006 | 113 | 0.300 |
Why?
|
| Referral and Consultation | 3 | 2024 | 406 | 0.300 |
Why?
|
| Organizational Policy | 2 | 2021 | 47 | 0.300 |
Why?
|
| Program Development | 4 | 2017 | 203 | 0.290 |
Why?
|
| Multiple Sclerosis | 2 | 2023 | 207 | 0.290 |
Why?
|
| Physician-Patient Relations | 5 | 2014 | 399 | 0.290 |
Why?
|
| Dyslipidemias | 3 | 2022 | 34 | 0.290 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2022 | 657 | 0.290 |
Why?
|
| Stress, Psychological | 1 | 2012 | 442 | 0.290 |
Why?
|
| Diet | 3 | 2016 | 497 | 0.280 |
Why?
|
| Internship and Residency | 3 | 2022 | 748 | 0.280 |
Why?
|
| Safety-net Providers | 2 | 2017 | 30 | 0.260 |
Why?
|
| Behavior Control | 1 | 2006 | 15 | 0.260 |
Why?
|
| Aged | 19 | 2023 | 13424 | 0.260 |
Why?
|
| Follow-Up Studies | 10 | 2016 | 2341 | 0.260 |
Why?
|
| Postpartum Period | 3 | 2005 | 187 | 0.260 |
Why?
|
| Nicotinic Agonists | 1 | 2006 | 39 | 0.260 |
Why?
|
| Professional Competence | 1 | 2007 | 91 | 0.260 |
Why?
|
| Oral Health | 2 | 2023 | 62 | 0.250 |
Why?
|
| Tobacco Use | 3 | 2020 | 37 | 0.250 |
Why?
|
| Evidence-Based Medicine | 3 | 2023 | 443 | 0.250 |
Why?
|
| Mental Disorders | 2 | 2022 | 720 | 0.240 |
Why?
|
| Anxiety Disorders | 3 | 2023 | 187 | 0.240 |
Why?
|
| Odds Ratio | 3 | 2014 | 748 | 0.240 |
Why?
|
| Health Equity | 2 | 2023 | 42 | 0.240 |
Why?
|
| Vitamins | 2 | 2022 | 74 | 0.230 |
Why?
|
| Certification | 2 | 2003 | 46 | 0.230 |
Why?
|
| Blood Pressure Determination | 2 | 2021 | 37 | 0.230 |
Why?
|
| Physicians | 2 | 2023 | 442 | 0.230 |
Why?
|
| Students | 3 | 2018 | 202 | 0.220 |
Why?
|
| Data Collection | 3 | 2011 | 372 | 0.220 |
Why?
|
| Periodontal Diseases | 1 | 2023 | 17 | 0.220 |
Why?
|
| Mentoring | 1 | 2024 | 46 | 0.220 |
Why?
|
| Sensitivity and Specificity | 6 | 2021 | 1097 | 0.210 |
Why?
|
| Boston | 6 | 2017 | 247 | 0.210 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2003 | 13 | 0.210 |
Why?
|
| Asymptomatic Infections | 2 | 2020 | 18 | 0.210 |
Why?
|
| Herpes Genitalis | 1 | 2023 | 2 | 0.210 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2022 | 94 | 0.210 |
Why?
|
| Herpesvirus 2, Human | 1 | 2023 | 10 | 0.210 |
Why?
|
| Substance-Related Disorders | 2 | 2020 | 687 | 0.210 |
Why?
|
| Serologic Tests | 1 | 2023 | 34 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 678 | 0.210 |
Why?
|
| Genes, BRCA1 | 2 | 2019 | 16 | 0.200 |
Why?
|
| Genes, BRCA2 | 2 | 2019 | 11 | 0.200 |
Why?
|
| Progestins | 1 | 2022 | 29 | 0.200 |
Why?
|
| Reference Values | 3 | 2020 | 326 | 0.200 |
Why?
|
| Hormone Replacement Therapy | 1 | 2022 | 28 | 0.200 |
Why?
|
| Vision Screening | 1 | 2022 | 8 | 0.200 |
Why?
|
| Hormones | 1 | 2022 | 60 | 0.200 |
Why?
|
| Educational Personnel | 1 | 2022 | 8 | 0.200 |
Why?
|
| Minerals | 1 | 2022 | 18 | 0.200 |
Why?
|
| Sexual Behavior | 2 | 2021 | 189 | 0.200 |
Why?
|
| Child, Preschool | 7 | 2023 | 1794 | 0.200 |
Why?
|
| Syphilis | 1 | 2022 | 25 | 0.200 |
Why?
|
| Herpesvirus 1, Human | 1 | 2023 | 78 | 0.200 |
Why?
|
| Administration, Inhalation | 2 | 2019 | 145 | 0.200 |
Why?
|
| HIV Infections | 2 | 2019 | 914 | 0.190 |
Why?
|
| Premature Birth | 2 | 2021 | 108 | 0.190 |
Why?
|
| Estrogens | 1 | 2022 | 109 | 0.190 |
Why?
|
| Cariostatic Agents | 1 | 2021 | 7 | 0.190 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 122 | 0.190 |
Why?
|
| Vision Disorders | 1 | 2022 | 59 | 0.190 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2022 | 37 | 0.190 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2022 | 54 | 0.190 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 16 | 0.190 |
Why?
|
| Guideline Adherence | 2 | 2005 | 296 | 0.190 |
Why?
|
| Fluorides, Topical | 1 | 2021 | 19 | 0.190 |
Why?
|
| Suicide | 1 | 2023 | 119 | 0.190 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 263 | 0.190 |
Why?
|
| Feeding and Eating Disorders | 1 | 2022 | 49 | 0.180 |
Why?
|
| Occult Blood | 1 | 2021 | 16 | 0.180 |
Why?
|
| Postmenopause | 1 | 2022 | 224 | 0.180 |
Why?
|
| Learning | 2 | 2022 | 171 | 0.180 |
Why?
|
| Pregnant Women | 2 | 2019 | 84 | 0.180 |
Why?
|
| Hepatitis B, Chronic | 1 | 2020 | 4 | 0.180 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2020 | 17 | 0.180 |
Why?
|
| Chlamydia Infections | 1 | 2021 | 76 | 0.180 |
Why?
|
| Healthy Lifestyle | 1 | 2021 | 27 | 0.180 |
Why?
|
| England | 1 | 2020 | 24 | 0.180 |
Why?
|
| Inservice Training | 2 | 2019 | 81 | 0.180 |
Why?
|
| Vitamin D Deficiency | 1 | 2021 | 41 | 0.180 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 1118 | 0.180 |
Why?
|
| Colonoscopy | 1 | 2021 | 86 | 0.180 |
Why?
|
| Curriculum | 3 | 2021 | 561 | 0.180 |
Why?
|
| Carotid Arteries | 1 | 2021 | 62 | 0.170 |
Why?
|
| Pre-Eclampsia | 1 | 2021 | 70 | 0.170 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 208 | 0.170 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2021 | 47 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2021 | 135 | 0.170 |
Why?
|
| Education | 1 | 2000 | 68 | 0.170 |
Why?
|
| Vaginosis, Bacterial | 1 | 2020 | 13 | 0.170 |
Why?
|
| Specialization | 1 | 2000 | 78 | 0.170 |
Why?
|
| Anxiety | 1 | 2023 | 387 | 0.170 |
Why?
|
| Cluster Analysis | 3 | 2017 | 245 | 0.170 |
Why?
|
| Substance Abuse Detection | 1 | 2020 | 44 | 0.170 |
Why?
|
| Quality Indicators, Health Care | 1 | 2003 | 333 | 0.170 |
Why?
|
| Dietary Supplements | 1 | 2022 | 222 | 0.170 |
Why?
|
| Stakeholder Participation | 1 | 2019 | 22 | 0.170 |
Why?
|
| Prescription Drugs | 1 | 2020 | 47 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 202 | 0.160 |
Why?
|
| Vitamin D | 1 | 2021 | 132 | 0.160 |
Why?
|
| Poverty | 6 | 2014 | 283 | 0.160 |
Why?
|
| Bacteriuria | 1 | 2019 | 11 | 0.160 |
Why?
|
| Chronic Disease | 2 | 2022 | 717 | 0.160 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2019 | 15 | 0.160 |
Why?
|
| Genetic Counseling | 1 | 2019 | 15 | 0.160 |
Why?
|
| Aromatase Inhibitors | 1 | 2019 | 21 | 0.160 |
Why?
|
| Psychotherapy | 1 | 2020 | 92 | 0.160 |
Why?
|
| Carotid Stenosis | 1 | 2021 | 104 | 0.160 |
Why?
|
| Emtricitabine | 1 | 2019 | 8 | 0.160 |
Why?
|
| Tenofovir | 1 | 2019 | 8 | 0.160 |
Why?
|
| Tamoxifen | 1 | 2019 | 35 | 0.160 |
Why?
|
| Hepatitis B | 1 | 2019 | 28 | 0.160 |
Why?
|
| Gonorrhea | 1 | 2021 | 179 | 0.160 |
Why?
|
| Diabetes, Gestational | 1 | 2021 | 138 | 0.160 |
Why?
|
| Lead Poisoning | 1 | 2019 | 10 | 0.160 |
Why?
|
| Physician's Role | 2 | 1997 | 120 | 0.160 |
Why?
|
| Lead | 1 | 2019 | 41 | 0.160 |
Why?
|
| Hepatitis C, Chronic | 1 | 2020 | 88 | 0.160 |
Why?
|
| Interview, Psychological | 1 | 1999 | 73 | 0.150 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2019 | 23 | 0.150 |
Why?
|
| Narcotic Antagonists | 1 | 2020 | 121 | 0.150 |
Why?
|
| Feedback | 1 | 2018 | 87 | 0.150 |
Why?
|
| Dietary Sugars | 1 | 2018 | 9 | 0.150 |
Why?
|
| Genetic Testing | 1 | 2019 | 126 | 0.150 |
Why?
|
| Hepacivirus | 1 | 2020 | 140 | 0.150 |
Why?
|
| Community Networks | 2 | 2011 | 30 | 0.150 |
Why?
|
| Depression | 4 | 2023 | 829 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 130 | 0.150 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 106 | 0.150 |
Why?
|
| Stroke | 3 | 2022 | 1128 | 0.150 |
Why?
|
| Family Health | 1 | 2018 | 67 | 0.150 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 53 | 0.140 |
Why?
|
| Beverages | 1 | 2018 | 66 | 0.140 |
Why?
|
| Mentors | 1 | 2018 | 116 | 0.140 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 43 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2015 | 1560 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2020 | 342 | 0.140 |
Why?
|
| Mental Health Services | 1 | 2000 | 269 | 0.140 |
Why?
|
| Patient Care Planning | 1 | 2017 | 84 | 0.140 |
Why?
|
| Smokers | 3 | 2023 | 116 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 1513 | 0.130 |
Why?
|
| Body Image | 1 | 2016 | 29 | 0.130 |
Why?
|
| Maternal Health Services | 1 | 2017 | 63 | 0.130 |
Why?
|
| Body Weights and Measures | 1 | 2016 | 33 | 0.130 |
Why?
|
| Risk Reduction Behavior | 3 | 2021 | 121 | 0.130 |
Why?
|
| Patient Compliance | 3 | 2011 | 349 | 0.130 |
Why?
|
| Dementia | 1 | 2020 | 248 | 0.130 |
Why?
|
| Community Mental Health Services | 1 | 2017 | 88 | 0.130 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 584 | 0.130 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2019 | 236 | 0.130 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2015 | 57 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 331 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 309 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 4 | 2022 | 706 | 0.120 |
Why?
|
| Middle East | 1 | 2015 | 6 | 0.120 |
Why?
|
| Jordan | 1 | 2015 | 1 | 0.120 |
Why?
|
| Patient-Centered Care | 2 | 2017 | 246 | 0.120 |
Why?
|
| Arabs | 1 | 2015 | 6 | 0.120 |
Why?
|
| Nurse's Role | 2 | 2017 | 116 | 0.120 |
Why?
|
| Education, Nonprofessional | 1 | 2015 | 5 | 0.120 |
Why?
|
| Patient Participation | 1 | 2017 | 216 | 0.120 |
Why?
|
| Depression, Postpartum | 2 | 2017 | 131 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2017 | 3072 | 0.120 |
Why?
|
| Faculty | 1 | 2015 | 51 | 0.120 |
Why?
|
| Glycemic Index | 1 | 2014 | 22 | 0.120 |
Why?
|
| Logistic Models | 2 | 2016 | 1236 | 0.110 |
Why?
|
| Efficiency, Organizational | 1 | 2015 | 93 | 0.110 |
Why?
|
| Mutation | 2 | 2019 | 2458 | 0.110 |
Why?
|
| Friends | 1 | 2014 | 29 | 0.110 |
Why?
|
| Multilevel Analysis | 1 | 2013 | 6 | 0.110 |
Why?
|
| Longitudinal Studies | 4 | 2024 | 1188 | 0.110 |
Why?
|
| Decision Making | 1 | 2017 | 395 | 0.110 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 805 | 0.110 |
Why?
|
| Organizational Case Studies | 2 | 2011 | 40 | 0.110 |
Why?
|
| Social Environment | 1 | 2013 | 91 | 0.100 |
Why?
|
| Linear Models | 3 | 2011 | 403 | 0.100 |
Why?
|
| Social Stigma | 1 | 2013 | 64 | 0.100 |
Why?
|
| Organizational Culture | 1 | 2013 | 106 | 0.100 |
Why?
|
| Factor Analysis, Statistical | 1 | 2013 | 98 | 0.100 |
Why?
|
| Personal Autonomy | 3 | 2007 | 68 | 0.100 |
Why?
|
| Adaptation, Psychological | 1 | 2014 | 259 | 0.100 |
Why?
|
| Socioeconomic Factors | 4 | 2017 | 742 | 0.100 |
Why?
|
| Neoplasms | 1 | 2022 | 1232 | 0.100 |
Why?
|
| Community Health Services | 1 | 2013 | 120 | 0.100 |
Why?
|
| Respiratory Function Tests | 1 | 2012 | 189 | 0.090 |
Why?
|
| Pediatricians | 2 | 2023 | 50 | 0.090 |
Why?
|
| Occupational Diseases | 1 | 2013 | 263 | 0.090 |
Why?
|
| Age Factors | 3 | 2021 | 1505 | 0.090 |
Why?
|
| Nutrition Surveys | 2 | 2022 | 131 | 0.090 |
Why?
|
| Financing, Government | 1 | 2011 | 30 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2011 | 242 | 0.090 |
Why?
|
| Social Behavior | 1 | 2011 | 87 | 0.090 |
Why?
|
| Minority Groups | 2 | 2022 | 135 | 0.090 |
Why?
|
| False Positive Reactions | 2 | 2021 | 76 | 0.090 |
Why?
|
| Vaccination | 2 | 2023 | 335 | 0.080 |
Why?
|
| Mental Health | 2 | 2022 | 336 | 0.080 |
Why?
|
| Self-Help Groups | 1 | 2009 | 37 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2023 | 1286 | 0.080 |
Why?
|
| Infant | 4 | 2019 | 1493 | 0.080 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2019 | 71 | 0.080 |
Why?
|
| Clinical Decision-Making | 2 | 2022 | 148 | 0.080 |
Why?
|
| Alcohol Drinking | 2 | 2020 | 288 | 0.080 |
Why?
|
| Family Practice | 2 | 2003 | 208 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2019 | 138 | 0.080 |
Why?
|
| Nurses | 1 | 2009 | 102 | 0.070 |
Why?
|
| Cost of Illness | 2 | 2019 | 156 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 617 | 0.070 |
Why?
|
| Practice Management, Medical | 1 | 2008 | 21 | 0.070 |
Why?
|
| Ultrasonography | 2 | 2021 | 458 | 0.070 |
Why?
|
| Probability | 1 | 2008 | 168 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 209 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 5126 | 0.070 |
Why?
|
| Administration, Sublingual | 1 | 2006 | 3 | 0.070 |
Why?
|
| Behavior, Addictive | 1 | 2007 | 72 | 0.070 |
Why?
|
| Absenteeism | 2 | 2017 | 38 | 0.070 |
Why?
|
| Disease Susceptibility | 2 | 2022 | 157 | 0.070 |
Why?
|
| Time Factors | 2 | 2011 | 3621 | 0.070 |
Why?
|
| Tobacco Products | 2 | 2018 | 71 | 0.060 |
Why?
|
| Sex Factors | 3 | 2019 | 935 | 0.060 |
Why?
|
| Blood Glucose | 2 | 2021 | 461 | 0.060 |
Why?
|
| Health Care Surveys | 2 | 2005 | 279 | 0.060 |
Why?
|
| Patient Preference | 2 | 2017 | 78 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1028 | 0.060 |
Why?
|
| Prenatal Care | 3 | 2002 | 170 | 0.060 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2024 | 36 | 0.060 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2024 | 29 | 0.060 |
Why?
|
| Stomatognathic Diseases | 1 | 2023 | 1 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 737 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2003 | 31 | 0.050 |
Why?
|
| Psychometrics | 1 | 2005 | 362 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2003 | 95 | 0.050 |
Why?
|
| Child Behavior | 1 | 2003 | 63 | 0.050 |
Why?
|
| Fear | 1 | 2023 | 65 | 0.050 |
Why?
|
| Puerperal Disorders | 1 | 2002 | 15 | 0.050 |
Why?
|
| Temperance | 1 | 2002 | 13 | 0.050 |
Why?
|
| Physicians, Family | 1 | 2003 | 75 | 0.050 |
Why?
|
| Herpes Simplex | 1 | 2023 | 48 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2003 | 129 | 0.050 |
Why?
|
| Regression Analysis | 3 | 1999 | 487 | 0.050 |
Why?
|
| Emergency Service, Hospital | 2 | 2022 | 1022 | 0.050 |
Why?
|
| Blindness | 1 | 2022 | 38 | 0.050 |
Why?
|
| Diagnosis, Oral | 1 | 2021 | 1 | 0.050 |
Why?
|
| Forecasting | 1 | 2023 | 221 | 0.050 |
Why?
|
| Prevalence | 2 | 2022 | 1255 | 0.050 |
Why?
|
| Vitamin E | 1 | 2022 | 52 | 0.050 |
Why?
|
| Perinatal Death | 1 | 2021 | 5 | 0.050 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2021 | 24 | 0.050 |
Why?
|
| Pregnancy Trimesters | 1 | 2021 | 10 | 0.050 |
Why?
|
| beta Carotene | 1 | 2022 | 64 | 0.050 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2021 | 27 | 0.050 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 27 | 0.050 |
Why?
|
| Visual Acuity | 1 | 2022 | 117 | 0.050 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2021 | 34 | 0.050 |
Why?
|
| Sigmoidoscopy | 1 | 2021 | 17 | 0.050 |
Why?
|
| Hearing Tests | 1 | 2021 | 3 | 0.050 |
Why?
|
| Fetal Macrosomia | 1 | 2021 | 12 | 0.050 |
Why?
|
| Hearing Aids | 1 | 2021 | 4 | 0.050 |
Why?
|
| Glucose Tolerance Test | 1 | 2021 | 96 | 0.050 |
Why?
|
| Precision Medicine | 1 | 2022 | 102 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2003 | 440 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2002 | 212 | 0.040 |
Why?
|
| Ischemic Attack, Transient | 1 | 2022 | 90 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2005 | 413 | 0.040 |
Why?
|
| Hepatitis B Vaccines | 1 | 2020 | 13 | 0.040 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2021 | 36 | 0.040 |
Why?
|
| Hearing Loss | 1 | 2021 | 45 | 0.040 |
Why?
|
| Physician Assistants | 1 | 2020 | 36 | 0.040 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 34 | 0.040 |
Why?
|
| Risk | 1 | 2021 | 364 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 260 | 0.040 |
Why?
|
| Marijuana Abuse | 1 | 2020 | 20 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 289 | 0.040 |
Why?
|
| Hepatitis C Antibodies | 1 | 2020 | 8 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 110 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 354 | 0.040 |
Why?
|
| Patient Selection | 1 | 2022 | 465 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2021 | 178 | 0.040 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2019 | 3 | 0.040 |
Why?
|
| Pyelonephritis | 1 | 2019 | 7 | 0.040 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2019 | 17 | 0.040 |
Why?
|
| Independent Living | 1 | 2020 | 44 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2020 | 91 | 0.040 |
Why?
|
| Nurse Practitioners | 1 | 2020 | 113 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2022 | 459 | 0.040 |
Why?
|
| Postnatal Care | 1 | 2000 | 41 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2019 | 24 | 0.040 |
Why?
|
| Aortic Rupture | 1 | 2019 | 54 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 445 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 527 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 90 | 0.040 |
Why?
|
| Immunoassay | 1 | 2019 | 68 | 0.040 |
Why?
|
| HIV | 1 | 2019 | 68 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2000 | 208 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2022 | 524 | 0.040 |
Why?
|
| Pancreas | 1 | 2019 | 146 | 0.040 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 80 | 0.040 |
Why?
|
| Canada | 1 | 2018 | 147 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2020 | 143 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 355 | 0.040 |
Why?
|
| Analysis of Variance | 4 | 2002 | 591 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 372 | 0.040 |
Why?
|
| Psychosocial Deprivation | 1 | 1997 | 8 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 451 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 480 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 903 | 0.040 |
Why?
|
| Self Concept | 1 | 1997 | 105 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 313 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2000 | 693 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 1119 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 359 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 920 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 676 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 264 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 863 | 0.030 |
Why?
|
| Social Desirability | 1 | 1995 | 6 | 0.030 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 1995 | 9 | 0.030 |
Why?
|
| Diet Records | 1 | 1995 | 34 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2014 | 28 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2014 | 45 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 1293 | 0.030 |
Why?
|
| Truth Disclosure | 1 | 1995 | 57 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2015 | 84 | 0.030 |
Why?
|
| Goals | 1 | 2015 | 88 | 0.030 |
Why?
|
| Bias | 1 | 1995 | 108 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2017 | 6079 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1597 | 0.030 |
Why?
|
| Energy Intake | 1 | 2014 | 167 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 353 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2016 | 2377 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 163 | 0.030 |
Why?
|
| Disease Management | 1 | 2015 | 220 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1993 | 103 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2015 | 329 | 0.030 |
Why?
|
| Health Status | 1 | 2015 | 426 | 0.020 |
Why?
|
| Relaxation Therapy | 1 | 1992 | 25 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2014 | 496 | 0.020 |
Why?
|
| Internal Medicine | 1 | 1993 | 154 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 1993 | 415 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2009 | 101 | 0.020 |
Why?
|
| Thymectomy | 1 | 1978 | 34 | 0.020 |
Why?
|
| BCG Vaccine | 1 | 1978 | 45 | 0.020 |
Why?
|
| Mycobacterium bovis | 1 | 1978 | 27 | 0.020 |
Why?
|
| Relaxation | 1 | 2007 | 6 | 0.020 |
Why?
|
| Amyloidosis | 1 | 1978 | 62 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2007 | 33 | 0.020 |
Why?
|
| Cotinine | 1 | 2007 | 19 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2007 | 45 | 0.020 |
Why?
|
| Saliva | 1 | 2007 | 100 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2007 | 131 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1978 | 237 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 674 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1978 | 323 | 0.020 |
Why?
|
| Incidence | 1 | 2007 | 1239 | 0.010 |
Why?
|
| Social Conditions | 1 | 2003 | 5 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2004 | 151 | 0.010 |
Why?
|
| Schizophrenia | 1 | 1976 | 247 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2005 | 256 | 0.010 |
Why?
|
| Antipsychotic Agents | 1 | 1976 | 293 | 0.010 |
Why?
|
| Nutritional Sciences | 1 | 2002 | 31 | 0.010 |
Why?
|
| Food Services | 1 | 2002 | 27 | 0.010 |
Why?
|
| Research | 1 | 2003 | 188 | 0.010 |
Why?
|
| Health Policy | 1 | 2003 | 177 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 409 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2002 | 187 | 0.010 |
Why?
|
| Leadership | 1 | 2003 | 195 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2000 | 514 | 0.010 |
Why?
|
| Chewing Gum | 1 | 1994 | 8 | 0.010 |
Why?
|
| Agoraphobia | 1 | 1992 | 11 | 0.010 |
Why?
|
| Personality Inventory | 1 | 1992 | 54 | 0.010 |
Why?
|
| Panic Disorder | 1 | 1992 | 32 | 0.010 |
Why?
|
| Awareness | 1 | 1992 | 74 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1992 | 380 | 0.010 |
Why?
|
| Algorithms | 1 | 1994 | 979 | 0.000 |
Why?
|
| Methylcholanthrene | 1 | 1978 | 2 | 0.000 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 1978 | 3 | 0.000 |
Why?
|
| Neoplasms, Experimental | 1 | 1978 | 75 | 0.000 |
Why?
|
| Rabbits | 1 | 1978 | 323 | 0.000 |
Why?
|
| Cell Wall | 1 | 1978 | 116 | 0.000 |
Why?
|
| Promazine | 1 | 1976 | 1 | 0.000 |
Why?
|
| Trifluoperazine | 1 | 1976 | 3 | 0.000 |
Why?
|
| Chlorpromazine | 1 | 1976 | 7 | 0.000 |
Why?
|
| Basal Ganglia Diseases | 1 | 1976 | 5 | 0.000 |
Why?
|
| Movement Disorders | 1 | 1976 | 22 | 0.000 |
Why?
|
| Recurrence | 1 | 1976 | 603 | 0.000 |
Why?
|
| Animals | 1 | 1978 | 19667 | 0.000 |
Why?
|